Brind.

Laprophan Share Sale Draws Near Seven Times Demand in Casablanca

1 report, 1 independent Updated Fri 10:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Laprophan, a Moroccan drug maker, conducted a share sale in Casablanca that drew provisional orders worth about MAD 15.3 billion. The offer was capped at MAD 2.22 billion, meaning demand was nearly seven times the number of shares available. The shares are scheduled to begin trading on the Casablanca Stock Exchange on November 25, 2026.

From riotimesonline.com

Why it matters

Some supportBrind's analysis of the reports

The successful capital increase provides funding for Laprophan. The company reported 2025 consolidated revenue of MAD 1.82 billion and a net profit of MAD 109 million, which represented a 33.9% increase.

From riotimesonline.com

Who's involved

  • LaprophanMoroccan drug maker conducting the share sale and listing.
  • MoroccoSovereign state where Laprophan operates and the market is located.
  • CasablancaLocation of the Casablanca Stock Exchange where the shares will be listed.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • LaprophanSpeculative

    Laprophan might receive massive funding through the successful share placement.

  • MoroccoSpeculative

    The Moroccan market may see increased confidence in the pharmaceutical sector following the capital influx.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped